Can opportunistic case-finding of paraproteins be clinically justified?

Annals of Clinical Biochemistry

Volumn 42, Issue 4, 2005, Pages 245-253

  Beetham, Robert ^a   Howie, Neil ^b   Soutar, Richard ^c  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBULIN; PARAPROTEIN; PLASMA PROTEIN;

AMYLOIDOSIS; B LYMPHOCYTE; CANCER CELL; CASE FINDING; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MEDICAL ETHICS; MEDICAL SOCIETY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; REVIEW; SCREENING TEST; UNITED KINGDOM;

ALGORITHMS; BLOOD PROTEIN ELECTROPHORESIS; GREAT BRITAIN; HUMANS; LYMPHOMA, B-CELL; PARAPROTEINEMIAS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 21844474818     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563054255515     Document Type: Review

References (22)

1. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57
2. Whicher JT, Spence CE. Serum protein zone electrophoresis - an outmoded test. Ann Clin Biochem 1987; 24: 133-9
3. Bernett A, Allerhand J, Efremides AP, Clejan S. Long term study of gammopathies. Clinically benign cases showing transition to malignant plasmacytomas after long periods of transition. Clin Biochem 1986; 19: 244-9
4. Beetham R, Reeve L, Goodrick J, Lester G. Discretionary requesting of electrophoresis - to what end? In: Ward AM, Martin SM (eds). Proceedings of CAPA 2001. Sheffield, UK: PRU Publications 2001; 91
5. UK Myeloma Forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115: 522-40
6. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic myeloma. Br J Haematol 1997; 97: 810-4
7. Kyle RA, Therneu TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New Engl J Med 2002; 346: 564-9
8. Rajkumar SV, Kyle RA, Therneu TM, et al. Presence of monoclonal free light chains predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127: 308-10
9. Lust JA, Donovan KA, Griepp PR. Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma In: Gahrton G, Durie BGM, Samson DM, eds. Multiple Myeloma and Related Disorders. London: Arnold, 2004; 369-78
10. Guidelines on the Diagnosis and Management of Multiple Myeloma. UK Myeloma Forum and Nordic Myeloma Study Group, 2005: (in press; www.bcshguidelines.com)
11. Barillé-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Haematology (Am Soc Haematol Educ Program) 2003; 248-78
12. Tian E, Zhan F, Walker R, et al. The role of the wnt-signalling antagonist DKKI in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 249: 2483-94
13. Politou M, Terpos, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126: 686-9
14. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996; 87: 4762-9
15. Melton III RJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19: 25-30
16. Kyle RA, Rajkumar SV. Drug therapy: multiple myeloma. N Engl J Med 2004; 351: 1860-73
17. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukaemia 2003; 17: 775-9
18. Hayden K, van Heyningen C. Measurement of total protein is a useful inclusion in liver function test profiles. Clin Chem 2001; 47: 793-7
19. Merlini G, Aguzzi F, Whicher J. Monoclonal B-cell proliferation In: Ritchie RF, Navolotskaia O, eds. Serum Proteins in Clinical Medicine Vol II. Scarborough, Maine: Foundation for Blood Research 1999; 107.04-13
20. Wilson JM, Yungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-393
21. Cancer Research UK. CancerStats Monograph 2004; http://www.info. cancerresearchuk.org/images/publicationspdf/cancerstats_incidence.pdf
22. Watts B, Burnett L, Chesher D. Measurement of total protein is not a useful inclusion in liver function test profiles. Clin Chem 2000; 46: 1022-3